# Thermo Fisher Scientific Inc. (TMO)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/TMO/primer

## Business Model

---
ticker: TMO
step: 01
generated: 2026-05-12
source: quick-research
---

### Thermo Fisher Scientific Inc. (TMO) — Business Overview

#### Business Description
Thermo Fisher Scientific is the world's largest life-sciences tools and services company, serving customers across pharma/biotech, hospitals/diagnostic labs, academic research, government, and industrial markets. The company combines analytical instruments, biosciences reagents, clinical trial services, lab equipment, specialty diagnostics, and bioprocessing/filtration into one platform. The platform thesis is "the trusted partner for life sciences innovation" — Thermo Fisher provides everything a pharma customer needs from drug discovery through clinical trial through commercial manufacturing. Recent acquisitions (Solventum filtration $4.0B; Clario clinical-trial tech) have expanded bioproduction depth.

#### Revenue Model
Four reportable segments:
- **Laboratory Products and Biopharma Services** (~$24.0B, ~54% of revenue, +4%) — Lab equipment (refrigerators, freezers, plastics, chemicals); pharma services (clinical-trial logistics, packaging, biologics CDMO via Patheon).
- **Life Sciences Solutions** (~$10.4B, ~23%, +8%) — Biosciences (reagents, antibodies, cell culture), Genetic Sciences (qPCR, NGS via Ion Torrent), Bioproduction (single-use technologies, gene therapy, cell culture media + the new Solventum filtration assets).
- **Analytical Instruments** (~$7.5B, ~17%, flat) — Mass spec (Q Exactive, Orbitrap), chromatography, X-ray, electron microscopy.
- **Specialty Diagnostics** (~$4.7B, ~10%, +4%) — Allergy, autoimmune, transplant diagnostics, microbiology, ImmunoCAP.

Revenue mix is roughly 80% recurring (consumables, services, instrument-attached consumables) — a key structural quality.

#### Products & Services
- **Bioproduction**: Single-use bioreactors (HyClone), cell culture media (Gibco), filtration (Cytiva-class via Solventum acquisition), Patheon biologics CDMO.
- **Analytical Instruments**: Orbitrap mass spec (industry standard for proteomics), Q Exactive (small molecule), electron microscopy (Thermo Fisher acquired FEI), X-ray.
- **Genetic Sciences**: TaqMan qPCR, Ion Torrent NGS, microarrays.
- **Pharma Services**: Clinical trial logistics (Fisher Clinical Services), packaging, CDMO (Patheon), Clario clinical-trial tech.
- **Lab Products**: Refrigerators, freezers, chemicals, plastics under Fisher Scientific channel.
- **Diagnostics**: ImmunoCAP (allergy), Phadia, transplant diagnostics.

#### Customer Base & Go-to-Market
- **Pharma / Biotech** (~50% of revenue): All top 20 pharma globally; thousands of biotechs; gold standard for drug discovery through commercial production.
- **Hospitals / Clinical Diagnostics** (~15%): Reference labs, hospital systems, blood banks.
- **Academic / Government** (~15%): Universities, NIH-funded labs, government research institutions.
- **Industrial / Applied** (~20%): Food/beverage, semiconductor, environmental, forensics, materials science.

Distribution: ~Fisher Scientific catalog/e-commerce platform (over 2M SKUs); direct sales force for instruments; channel partners; pharma services contracted directly.

#### Competitive Position
Thermo Fisher is the largest "picks and shovels" play in life sciences — broader product breadth than any peer (Danaher's biotech/diagnostic group, Agilent, Waters, PerkinElmer, Bio-Rad, Sartorius, Merck KGaA Life Science). Structural advantages:

1. **Scale + breadth** — Only company with end-to-end coverage from research through clinical trial through commercial production. Average top-100 pharma customer spends $200M+/year with Thermo Fisher.
2. **Recurring revenue** — ~80% recurring (consumables, services, attached reagents); creates compounding earnings even when capital-equipment cycle softens.
3. **Patheon + Solventum + Clario** — Strategic acquisitions building the most complete biologics/cell-and-gene-therapy CDMO and clinical-trial services stack.
4. **PPI (Practical Process Improvement)** — Operational productivity culture; consistently delivers 50–100 bps of operating margin expansion in normal years.
5. **M&A track record** — Excellent capital allocator (Patheon, Affymetrix, FEI, Qiagen Life Sciences, BD Allergy, PPD ($17.4B), Olink, Solventum filtration, Clario). Compounder model.

**Current cyclical challenges:** Pharma R&D budget pressure (post-2023 biotech funding pullback still working through); China headwinds (anti-corruption + IRA-style anti-Western technology policies); academic/government funding pressures (US continuing resolutions); pandemic-era runoff finally normalizing.

#### Key Facts
- Founded: 1956 (Thermo Electron); merged with Fisher Scientific 2006
- Headquarters: Waltham, Massachusetts
- Employees: ~125,000
- Exchange: NYSE
- Sector / Industry: Health Care / Life Sciences Tools & Services
- Market Cap: ~$200B
- 2025 Revenue: $44.6B (+4% YoY)
- Major Recent Acquisitions: Solventum filtration ($4.0B, 2025); Clario (clinical-trial tech, 2025); Olink ($3.1B, 2024); PPD ($17.4B, 2021)
- 2025 Capital Deployed: ~$16.5B (~$13B M&A + ~$3.6B buybacks/dividends)
- Adjusted ROIC: 11.3% (2025)

## Financial Snapshot

---
ticker: TMO
step: 04
generated: 2026-05-12
source: quick-research
---

### Thermo Fisher Scientific Inc. (TMO) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY (FY25) |
|--------|--------|--------|--------|------------|
| Revenue | $42.86B | $42.88B | $44.56B | +3.9% |
| Organic Revenue Growth | -3% | -1% | +2% | inflection to positive |
| Adjusted Operating Income | $10.07B | $9.71B | $10.11B | +4% |
| Adjusted Operating Margin | 23.5% | 22.6% | 22.7% | +10 bps |
| Adjusted EPS | $21.86 | $21.86 | $22.87 | +5% |
| GAAP Net Income | ~$6.0B | ~$6.3B | ~$6.5B | ~+3% |

#### Segment Detail (FY2025)

| Segment | FY25 Revenue | YoY | Organic |
|---------|--------------|-----|---------|
| Laboratory Products and Biopharma Services | $24.0B | +4% | +3% |
| Life Sciences Solutions | $10.4B | +8% | +3% |
| Analytical Instruments | $7.5B | +1% | flat |
| Specialty Diagnostics | $4.7B | +4% | +2% |

#### Cash Flow & Capital Allocation (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$8.5B |
| Free Cash Flow | ~$7.5B |
| Capital Deployed | $16.5B |
| M&A Spending | ~$13B (Solventum filtration + Clario pending + bolt-ons) |
| Buybacks + Dividends | ~$3.6B |
| Adjusted ROIC | 11.3% |
| Dividend Yield | ~0.4% (focus on growth + M&A) |
| Net Debt | ~$33B |
| Credit Rating | A- (S&P) |

#### 2026 Guidance

| Metric | 2026 Guide |
|--------|-----------|
| Revenue | $46.3–47.2B (+4–6% reported, +3–4% organic) |
| Adjusted Operating Margin | +50 bps expansion (despite -20 bps M&A dilution) |
| Adjusted EPS | $24.22–24.80 (+6–8% YoY) |
| Pending M&A | Clario acquisition ($9B, expected close YE 2026) |

#### Key Ratios (approximate)
- P/E: ~22x (FY25 adjusted) | EV/EBITDA: ~17x | FCF Yield: ~3.8%
- Revenue Growth (FY25): +3.9% (reported); +2% organic
- Adjusted Operating Margin: 22.7%
- Adjusted ROIC: 11.3%

#### Growth Profile
2025 marked a clear inflection: organic growth turned positive (+2% vs. -1% in FY24), operating margin expanded modestly (+10 bps), and the company deployed $13B+ in M&A on accretive assets (Solventum filtration + Clario). The post-COVID normalization (excess Covid testing revenue runoff completed) and biotech funding rebound (Series A/B funding picking up in H2 2025) set up a multi-year recovery in organic growth. 2026 guide of +3–4% organic growth + 50 bps margin expansion + 6–8% EPS growth represents the first "clean" year since the pandemic distortion.

#### Forward Estimates
2026 Guide:
- Revenue: $46.3–47.2B (midpoint $46.75B)
- Adjusted EPS: $24.22–24.80 (midpoint $24.51, +7%)

Bull case: Organic growth accelerates to +5–6% in 2027 on biotech funding rebound + Patheon CDMO ramp + bioproduction recovery; Clario adds 2 pts EPS accretion 2027 onward; ROIC expands to 13–14% by 2028. Bear case: pharma R&D budget pressure persists; China headwinds extend; biotech funding remains soft; organic growth stuck at +2–3%; EPS growth at low end of 6–8% range.

## Recent Catalysts

---
ticker: TMO
step: 12
generated: 2026-05-12
source: quick-research
---

### Thermo Fisher Scientific Inc. (TMO) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Organic growth inflection +2% in FY25 vs. -1% in FY24** — End of post-COVID Covid-testing runoff; biotech funding rebound starting (Series A/B funding picked up H2 2025); FY26 guide of +3–4% organic confirms inflection. Each ~100 bps of additional organic growth generates ~$0.80 of incremental adjusted EPS.
2. **Solventum filtration acquisition ($4.0B, closed 2025)** — Strengthens bioproduction filtration capabilities critical for biologics + gene-cell therapy manufacturing. Expected ~$125M of adjusted operating income synergies by year 5; double-digit IRR.
3. **Clario acquisition ($9B, closing YE 2026)** — Largest M&A since PPD ($17.4B in 2021). Adds clinical-trial technology (eClinical platforms, sensors, ePRO) that complements Patheon CDMO + Fisher Clinical Services. Multi-billion incremental revenue + EPS accretion 2027+.
4. **Bioproduction recovery** — Single-use technologies, cell culture media (Gibco), and filtration are seeing improving order patterns as biotech funding recovers and gene-cell therapy clinical-trial volumes ramp. This is the highest-margin growth driver in Life Sciences Solutions.
5. **PPI operational excellence + 50 bps margin expansion guide** — TMO's Practical Process Improvement culture consistently delivers margin gains. FY26 guide of +50 bps margin expansion (despite -20 bps M&A dilution) reflects organic productivity.
6. **Excellent M&A track record + compounder model** — Sub-10% IRR M&A is rare; TMO consistently delivers low-double-digit returns on acquisitions (Patheon, FEI, Olink, PPD, Solventum). Capital deployment at $13B+/yr is materially accretive.
7. **Strong recurring revenue mix (~80%)** — Consumables + services + attached reagents create earnings stability through capital-equipment cycles.

#### Bear Case Risks

1. **Pharma R&D budget pressure persists** — Top-20 pharma R&D spend is flat-to-down in 2026 on patent cliff pressures and IRA negotiation; smaller biotechs still recovering from 2022–24 funding drought. Total pharma R&D growth at ~3% lags TMO's organic growth ambitions.
2. **China headwinds extending** — Anti-corruption campaign and anti-Western technology policies create ongoing pressure on Chinese pharma + diagnostic spending. China is ~8% of TMO revenue.
3. **Academic / government funding pressure** — US continuing resolutions, NIH budget pressure, EU academic budget cuts. ~15% of TMO revenue exposed.
4. **Patheon CDMO competition + capacity glut** — Multiple biologics CDMOs (Lonza, Samsung Biologics, Catalent post-Novo) competing aggressively; pricing pressure on biologics manufacturing slots.
5. **M&A integration complexity** — Layering Solventum + Clario + smaller bolt-ons creates execution risk. Past acquisitions integrated well, but Clario at $9B is largest non-PPD deal.
6. **Mass spec capex cycle vulnerability** — Analytical Instruments (~17% of revenue) is most capital-equipment exposed; flat organic in FY25 reflects cyclical pause; further weakness possible.
7. **Tariff / IP localization pressure** — Multiple jurisdictions pushing localized clinical-trial data sovereignty; restrictive on TMO's global pharma-services + clinical-trial platforms.

#### Upcoming Events
- **Q2 2026 earnings (late July 2026)**: Mid-year FY26 guide check.
- **Clario acquisition close (expected YE 2026)**: First financial contribution + accretion disclosure 2027.
- **Biotech funding data**: Quarterly tracking of XBI biotech ETF + IPO/follow-on issuance.
- **Pharma R&D guidance updates**: Top-20 pharma capex/R&D announcements.
- **China policy environment**: Anti-corruption / data-localization developments.
- **NIH appropriations**: US government funding bills affecting academic research budgets.

#### Analyst Sentiment
Consensus rating is **Buy / Overweight** (~75% Buy, 23% Hold, 2% Sell). Price targets cluster $640–680 vs. trading ~$560–590 (~12–18% implied upside). Bull case targets ~$720 on organic acceleration + Clario integration; bear case ~$500 on persistent pharma/China headwinds. JPM, BofA, Morgan Stanley, BMO maintain Buy/Overweight; Bernstein at Equal-Weight given valuation.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/tmo
- Full research API: GET /api/v1/research/TMO/memo
- Coverage universe: /stocks